| Literature DB >> 29535291 |
Hisanori Fukunaga1,2, Yasuko Tatewaki1, Tatsushi Mutoh1, Hideo Shimomura1, Shuzo Yamamoto3,4, Chiaki Terao1, Tomoko Totsune1, Manabu Nakagawa1, Yasuyuki Taki1.
Abstract
BACKGROUND Primary cardiac lymphoma is rare and can be an aggressive disease, depending on the grade. A case is reported of low-grade primary cardiac lymphoma associated with a pericardial effusion. 18F-fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) imaging was useful in the diagnosis and in evaluating the disease activity in this case. CASE REPORT A 72-year-old Japanese woman visited a general practitioner, complaining of dyspnea associated with cardiac tamponade. Pericardiocentesis was performed, and Group V malignant cells were identified by cytology, suspicious for malignant lymphoma. Whole-body FDG-PET/CT scans showed no pleural effusion or lymph node metastasis supporting the diagnosis of primary cardiac lymphoma diagnosed on pericardial effusion. The laboratory investigations showed that levels of serum soluble interleukin-2 (IL-2) receptor (sIL-2R), a diagnostic and prognostic marker for malignant lymphoma, were not elevated (258 U/ml). A six-month follow-up FDG-PET/CT scan showed an increased volume of the pericardial effusion and mild but abnormal uptake diffusely in the pericardial space, and the sIL-2R was slightly elevated (860 U/ml). No abnormal FDG accumulation outside the retained pericardial effusion was noted, which was compatible with a clinical picture of low-grade primary cardiac lymphoma, and in a period of watchful waiting during the first two years later, the sIL-2R had reduced to 195 U/ml. CONCLUSIONS This is a rare case of low-grade primary cardiac lymphoma detected in a pericardial effusion, and highlights the utility of the FDG-PET/CT scan as a valuable diagnostic and follow-up modality.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29535291 PMCID: PMC5865403 DOI: 10.12659/ajcr.908385
Source DB: PubMed Journal: Am J Case Rep ISSN: 1941-5923
Figure 1.18F-fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) imaging. (A, D) Cardiac computed tomography (CT) imaging. (B, E) 18F-fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) fusion imaging. (C, F) Maximum intensity projection of a whole-body of FDG-PET imaging. The first FDG-PET examination (upper row) shows no pericardial effusion and no lymph node metastases. The second FDG-PET/CT examination was undergone six months after the first visit (lower row). The 18FDG uptake of the pericardial space using region of interest (ROI) diameter of 20 mm was measured and the maximum standardized uptake value (SUVmax: maximum ROI activity/[injected dose/body weight], with activity in megabecquerel [MBq] per gram, dose in MBq and weight in grams) was calculated. FDG-PET/CT showed an increased volume of the pericardial effusion and diffuse mild 18F-FDG uptake (SUVmax 2.7) corresponding to the retained pericardial effusion (D, E) and no lymph node metastasis (F).
Figure 2.Representative cardiac 18F-fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) images. (A) Pericardial and pleural effusions in congestive heart failure. Note that no or less uptake of 18F-FDG in the pleural effusion associated with heart failure when compared with primary cardiac lymphoma (Figure 1E). (B) An example of carcinomatous pericarditis and cardiac metastases from a case of lung cancer. Focal and high 18F-FDG uptake was observed in the left myocardium, and multiple areas of mild uptake in the pericardium were shown corresponding to cardiac metastases with carcinomatous pericarditis. A primary right lung cancer and multiple distant metastases can be identified as hot spots in the FDG-PET whole-body scan.